Effects of oestrogen on cardiovascular events in postmenopausal women

被引：0
|
作者：
Herrington, DM [1 ]
机构：
[1] Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Winston Salem, NC 27157 USA
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2001年 / 3卷 / 0M期
关键词：
cardiovascular disease; hormone replacement therapy; oestrogen. primary prevention; secondary prevention;
D O I：
10.1016/S1520-765X(01)90076-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A number of randomized clinical trials have investigated the role of hormone replacement therapy (HRT) in primary and secondary prevention of clinical and anatomical manifestations of atherosclerosis. There is mounting evidence that HRT does not slow the progression of clinical or anatomical manifestations of atherosclerosis in women with established disease. Indeed, there appears to be a pattern of increased risk among new users of HRT. In contrast, there are encouraging new data that suggest that HRT may be more effective in women who have not yet developed clinical manifestations of coronary disease. (C) 2001 The European Society of Cardiology.
引用
收藏
页码：M7 / M11
页数：5
相关论文
共 50 条
  • [21] Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: A randomised controlled trial
    de Kraker, Alyde T.
    Kenemans, Peter
    Smolders, Raimond G. V.
    Kroeks, Maurice V. A. M.
    van der Mooren, Marius J.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2009, 142 (02) : 139 - 144
  • [22] Risk factors for major adverse cardiovascular events in postmenopausal women: UK Biobank prospective cohort study
    Bertomeu-Gonzalez, Vicente
    Cordero, Alberto
    Ruiz-Nodar, Juan Miguel
    Sanchez-Ferrer, Francisco
    Lopez-Pineda, Adriana
    Quesada, Jose Antonio
    ATHEROSCLEROSIS, 2023, 386
  • [23] Cardiovascular risks in postmenopausal women receiving HRT
    Mueck, A. O.
    Seeger, H.
    GYNAKOLOGISCHE ENDOKRINOLOGIE, 2007, 5 (03): : 120 - 126
  • [24] Postmenopausal hormone therapy and cardiovascular disease in women
    Stefanick, M. L.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (06) : 451 - 458
  • [25] Cardiovascular disease (CVD) in hyperandrogenic postmenopausal women
    Meun, C.
    Kavousi, M.
    Jaspers, L.
    Muka, T.
    Duran, O. H. Franco
    Laven, J. S. E.
    HUMAN REPRODUCTION, 2015, 30 : 116 - 116
  • [26] Cardiovascular prevention in peri- and postmenopausal women
    Voychenko, N. A.
    Kuznetsova, I. V.
    Mychka, V. B.
    Kirillova, M. Yu.
    Tolstov, S. N.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2011, 10 (03): : 123 - 130
  • [27] Testosterone, SHBG and cardiovascular health in postmenopausal women
    J S Brand
    Y T van der Schouw
    International Journal of Impotence Research, 2010, 22 : 91 - 104
  • [28] Testosterone, SHBG and cardiovascular health in postmenopausal women
    Brand, J. S.
    van der Schouw, Y. T.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2010, 22 (02) : 91 - 104
  • [29] Lower Risk of Cardiovascular Events in Postmenopausal Women Taking Oral Estradiol Compared With Oral Conjugated Equine Estrogens
    Smith, Nicholas L.
    Blondon, Marc
    Wiggins, Kerri L.
    Harrington, Laura B.
    Vlieg, Astrid van Hylckama
    Floyd, James S.
    Hwang, Melody
    Bis, Joshua C.
    McKnight, Barbara
    Rice, Kenneth M.
    Lumley, Thomas
    Rosendaal, Frits R.
    Heckbert, Susan R.
    Psaty, Bruce M.
    JAMA INTERNAL MEDICINE, 2014, 174 (01) : 25 - 31
  • [30] Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women
    Teerlink, T
    Neele, SJM
    de Jong, S
    Netelenbos, JC
    Stehouwer, CDA
    CLINICAL SCIENCE, 2003, 105 (01) : 67 - 71
12345